Cargando…
A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine
Patient: Female, 59-year-old Final Diagnosis: Deep vein thrombosis • pulmonary embolism • thrombosis Symptoms: Chest pain • shortness of breath Medication: — Clinical Procedure: — Specialty: Hematology • Infectious Diseases • General and Internal Medicine OBJECTIVE: Unusual clinical course BACKGROUN...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212841/ https://www.ncbi.nlm.nih.gov/pubmed/34117206 http://dx.doi.org/10.12659/AJCR.932946 |
_version_ | 1783709715828572160 |
---|---|
author | Al-Maqbali, Juhaina Salim Rasbi, Sara Al Kashoub, Masoud Salim Hinaai, Asaad Mohammed Al Farhan, Hatem Rawahi, Bader Al Al Alawi, Abdullah M. |
author_facet | Al-Maqbali, Juhaina Salim Rasbi, Sara Al Kashoub, Masoud Salim Hinaai, Asaad Mohammed Al Farhan, Hatem Rawahi, Bader Al Al Alawi, Abdullah M. |
author_sort | Al-Maqbali, Juhaina Salim |
collection | PubMed |
description | Patient: Female, 59-year-old Final Diagnosis: Deep vein thrombosis • pulmonary embolism • thrombosis Symptoms: Chest pain • shortness of breath Medication: — Clinical Procedure: — Specialty: Hematology • Infectious Diseases • General and Internal Medicine OBJECTIVE: Unusual clinical course BACKGROUND: The COVID-19 pandemic is an ongoing cause of the current global healthcare crisis. Several vaccines were approved for use by emergency vaccination campaigns worldwide. At present, there are very few reports of COVID-19 vaccine-induced immune-thrombotic thrombocytopenia, a variant of heparin-induced thrombocytopenia (HIT), in comparison to the massive number of vaccinated people worldwide. CASE REPORT: A 59-year-old woman presented to the Emergency Department with a 3-day history of sudden-onset left leg pain 7 days after receiving her first dose of BNT162b2 mRNA COVID-19 (Pfizer-BioNTech). She was diagnosed with deep vein thrombosis (DVT) and pulmonary embolism (PE) and found to have a positive HIT screen with optical density (OD) of 0.6 via ELISA test. She was hospitalized for 4 days and discharged home with an oral anticoagulant (rivaroxaban). CONCLUSIONS: This case report describes a possible link between BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccination and thromboembolism. However, further data are needed to support such an association. |
format | Online Article Text |
id | pubmed-8212841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82128412021-06-29 A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine Al-Maqbali, Juhaina Salim Rasbi, Sara Al Kashoub, Masoud Salim Hinaai, Asaad Mohammed Al Farhan, Hatem Rawahi, Bader Al Al Alawi, Abdullah M. Am J Case Rep Articles Patient: Female, 59-year-old Final Diagnosis: Deep vein thrombosis • pulmonary embolism • thrombosis Symptoms: Chest pain • shortness of breath Medication: — Clinical Procedure: — Specialty: Hematology • Infectious Diseases • General and Internal Medicine OBJECTIVE: Unusual clinical course BACKGROUND: The COVID-19 pandemic is an ongoing cause of the current global healthcare crisis. Several vaccines were approved for use by emergency vaccination campaigns worldwide. At present, there are very few reports of COVID-19 vaccine-induced immune-thrombotic thrombocytopenia, a variant of heparin-induced thrombocytopenia (HIT), in comparison to the massive number of vaccinated people worldwide. CASE REPORT: A 59-year-old woman presented to the Emergency Department with a 3-day history of sudden-onset left leg pain 7 days after receiving her first dose of BNT162b2 mRNA COVID-19 (Pfizer-BioNTech). She was diagnosed with deep vein thrombosis (DVT) and pulmonary embolism (PE) and found to have a positive HIT screen with optical density (OD) of 0.6 via ELISA test. She was hospitalized for 4 days and discharged home with an oral anticoagulant (rivaroxaban). CONCLUSIONS: This case report describes a possible link between BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccination and thromboembolism. However, further data are needed to support such an association. International Scientific Literature, Inc. 2021-06-12 /pmc/articles/PMC8212841/ /pubmed/34117206 http://dx.doi.org/10.12659/AJCR.932946 Text en © Am J Case Rep, 2021 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Articles Al-Maqbali, Juhaina Salim Rasbi, Sara Al Kashoub, Masoud Salim Hinaai, Asaad Mohammed Al Farhan, Hatem Rawahi, Bader Al Al Alawi, Abdullah M. A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine |
title | A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine |
title_full | A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine |
title_fullStr | A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine |
title_full_unstemmed | A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine |
title_short | A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine |
title_sort | 59-year-old woman with extensive deep vein thrombosis and pulmonary thromboembolism 7 days following a first dose of the pfizer-biontech bnt162b2 mrna covid-19 vaccine |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212841/ https://www.ncbi.nlm.nih.gov/pubmed/34117206 http://dx.doi.org/10.12659/AJCR.932946 |
work_keys_str_mv | AT almaqbalijuhainasalim a59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT rasbisaraal a59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT kashoubmasoudsalim a59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT hinaaiasaadmohammedal a59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT farhanhatem a59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT rawahibaderal a59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT alalawiabdullahm a59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT almaqbalijuhainasalim 59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT rasbisaraal 59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT kashoubmasoudsalim 59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT hinaaiasaadmohammedal 59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT farhanhatem 59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT rawahibaderal 59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine AT alalawiabdullahm 59yearoldwomanwithextensivedeepveinthrombosisandpulmonarythromboembolism7daysfollowingafirstdoseofthepfizerbiontechbnt162b2mrnacovid19vaccine |